CD19 and non-Hodgkin lymphoma: Another first-in-human clinical trial of CD19-CAR-UCB-NK for relapsed or refractory CD19-positive non-Hodgkin’s lymphoma or chronic lymphocytic leukemia (CLL) was conducted in 11 patients.